VRDN logo

VRDN Viridian Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$29.96
-1.48 (-4.71%)

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinic…

Price

No data yet.

Social Signal Score

64
5d
70
1 mentions
—
30d
63
6 mentions
—
60d
62
7 mentions
—
90d
59
9 mentions
—
news: 9

Analyst Ratings

17 analysts
Buyconsensus
Strong Buy 0Buy 15Hold 2Sell 0Strong Sell 0
Avg price target$40+33.5%
Low $31Median $39High $47
Current Consensus

Revenue

$25.75M+3306.35%
$0.00$23.52M$47.05M$70.57M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-3.53
$-4.21–$-3.10
11 analysts
FY2026
$-3.54
$-3.94–$-3.24
11 analysts
FY2027
$-2.05
$-2.42–$-1.43
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Stephen F. Mahoney
Sector
Healthcare
Industry
Biotechnology
Employees
252
Beta
0.96
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
2.01
www.viridiantherapeutics.com